BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shenyang Sunshine Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shenyang Sunshine Pharmaceutical'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07233850-2740@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SSGJ-706: Phase 2 readout est. (NCT07233850)
DESCRIPTION:SSGJ-706\, phase 2.\nStudy: A Phase II Clinical Study Evaluatin
 g SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ssgj-706#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07233850
URL:https://assetmemo.bio/drug/ssgj-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227012-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227012)
DESCRIPTION:PF-08634404\, phase 1/2.\nStudy: Symbiotic-GI-13: A Study to Le
 arn About Study Medicine Called PF-08634404 as a Single Treatment and Comb
 ination Treatment in Adult Participants With a Liver Cancer Called Hepatoc
 ellular Carcinoma\, That is Too Advanced to be Removed by Surgery and May 
 Have Spread to Other Parts of the Body.\nEstimated primary completion: 18 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-0863
 4404#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07227012
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874984-2740@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SSGJ-706: Phase 2 readout est. (NCT07874984)
DESCRIPTION:SSGJ-706\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SPGL00
 8 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell
  Lung Cancer\nEstimated primary completion: November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ssgj-706#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07874984
URL:https://assetmemo.bio/drug/ssgj-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:PF-08634404\, phase 1/2.\nStudy: Symbiotic-GU-08: A Study to Le
 arn About the Medicine Called PF-08634404 Dosed Alone and in Combination W
 ith Other Anticancer Therapies in Adults With Locally Advanced or Metastat
 ic Renal Cell Cancer\nEstimated primary completion: 2 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07227415
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586074-3016@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Clifutinib Besylate: Phase 3 readout est. (NCT05586074)
DESCRIPTION:Clifutinib Besylate\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/clifutinib-besylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586074
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854276-906@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Loncipoetin alfa (NuPIAO): Phase 2 readout est. (NCT06854276)
DESCRIPTION:Loncipoetin alfa (NuPIAO)\, phase 2.\nStudy: Study of SSS06 for
  Chemotherapy-Induced Anemia in Non-Myeloid Malignancies\nEstimated primar
 y completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/loncipoetin-alfa-nupiao#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06854276
URL:https://assetmemo.bio/drug/loncipoetin-alfa-nupiao#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421700-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07421700)
DESCRIPTION:PF-08634404\, phase 1/2.\nStudy: Symbiotic-GU-06: A Study to Le
 arn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in U
 rothelial Cancer\nEstimated primary completion: 28 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07421700
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05133882-3016@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Clifutinib Besylate: Phase 1/2 readout est. (NCT05133882)
DESCRIPTION:Clifutinib Besylate\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Ch
 emotherapy in the Treatment of Newly Diagnosed AML\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/clifutinib-besylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05133882
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476287-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:PF-08634404: Phase 2 readout est. (NCT07476287)
DESCRIPTION:PF-08634404\, phase 2.\nStudy: Symbiotic-Lung-14: A Study to Le
 arn About the Study Medicine Called PF08634404 in Combination With Chemoth
 erapy in Adult Participants With Transformed Small Cell Lung Cancer\nEstim
 ated primary completion: 24 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07476287
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489066-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20280729
DTEND;VALUE=DATE:20280730
SUMMARY:PF-08634404: Phase 2 readout est. (NCT07489066)
DESCRIPTION:PF-08634404\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination
  in Early-stage or Locally Advanced NSCLC\nEstimated primary completion: 2
 9 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634
 404#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07489066
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222566-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222566)
DESCRIPTION:PF-08634404\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634
 404 in Combination With Chemotherapy in Adult Participants With Locally Ad
 vanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary complet
 ion: 27 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pf-08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07222566
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:PF-08634404\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 ymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-0863
 4404 in Combination With Different Anticancer Agents in Advanced Cancers\n
 Estimated primary completion: 8 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578649-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07578649)
DESCRIPTION:PF-08634404\, phase 3\, Endometrial Cancer.\nStudy: Symbiotic-G
 YN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Com
 bination With Chemotherapy in Adult Participants With Advanced or Recurren
 t MMR-proficient Endometrial Cancer\nEstimated primary completion: 1 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0757864
 9
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222800-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20300223
DTEND;VALUE=DATE:20300224
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222800)
DESCRIPTION:PF-08634404\, phase 3\, Colorectal Cancer.\nStudy: Symbiotic-GI
 -03: A Study to Learn About the Study Medicine Called PF-08634404 in Combi
 nation With Chemotherapy in Adult Participants With Metastatic Colorectal 
 Cancer\nEstimated primary completion: 23 February 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07222800
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226999-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:PF-08634404: Phase 2/3 readout est. (NCT07226999)
DESCRIPTION:PF-08634404\, phase 2/3.\nStudy: Symbiotic-Lung-04: A Study to 
 Learn About the Study Medicine Called PF-08634404 in Combination With Chem
 otherapy and With Tarlatamab\, Alone or With Chemotherapy\, in Adult Parti
 cipants With Extensive-Stage Small Cell Lung Cancer\nEstimated primary com
 pletion: 14 June 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pf-08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07226999
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392892-1989@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20310722
DTEND;VALUE=DATE:20310723
SUMMARY:PF-08634404: Phase 2/3 readout est. (NCT07392892)
DESCRIPTION:PF-08634404\, phase 2/3.\nStudy: Symbiotic-GI-16: A Study to Le
 arn About the Study Medicine Called PF-08634404 in Combination With Chemot
 herapy in Gastroesophageal Cancer\nEstimated primary completion: 22 July 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07392892
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
